In concordance with these claims, HER3/HER4 inhibition with an NRG1-targeted monoclonal antibody has been found to inhibit primary tumor growth and enhance the magnitude and duration of chemotherapy response in preclinical models, and to prevent disease relapse171. This evidence concerns the gene ERBB4 and neoplasm.